Drug Database
Back to search

Norway· NO-ID_61700E03-8D4E-49B3-A12B-37F77DFEA3AD

Byfavo

A remimazolam product containing remimazolam, registered in Norway by PAION Pharma GmbH. The same ATC class is registered in 14 of our 19 countries.

ATC N05CD14

Checked against FEST (Norway) on

Informational only — not a medical device.

SOURCE REGISTER · NOFEST (Norway)normalisedByfavoATCN05CD14REGISTER NO.NO-ID_61700E03-8D4E-4…PACKS LISTED3CHECKEDSeptember 25, 2026
Compare price across countriesPer daily dose · free accountAsk the assistant about remimazolamAnswers with sources · free accountCheck interactionsSeverity free · mechanism on Growth

Where it is registered

Remimazolam is registered in 14 of 19 countries.

Countries holding a registration under ATC N05CD14 (remimazolam), each read from that country’s own register.

  • This record: Norway, from FEST (Norway)
  • 9 of them publish a price we can compare per daily dose
Search remimazolam products by name

Remimazolam · ATC N05CD14

14 / 19 countries

  • Belgiumprice
  • Czechiaprice
  • Denmark
  • Finlandprice
  • Franceprice
  • Icelandprice
  • Ireland
  • Japan
  • Netherlands
  • Norwayprice
  • Polandprice
  • Spainprice
  • United Kingdom
  • United Statesprice
Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

The record

At a glance

FEST (Norway)
Active substance
Remimazolam
Manufacturer
PAION Pharma GmbH
Country
Norway (NO)
ATC code
N05CD14
ATC class
Remimazolam
Reimbursed
Not published by this register
Source register
FEST (Norway)
Last checked
September 25, 2026

Packs & prices · 3

1 priced
  • no_merkevare_id
    ID_61700E03-8D4E-49B3-A12B-37F77DFEA3AD
  • no_varenummer
    105945
    10 x 50
    NOK 6300.9
  • gtin
    4260727580193

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Interactions

71 interactions on record for remimazolam.

Graded by severity as the source publishes them — 4 severe. Severity grades are free for everyone; mechanism and management come with Growth.

  • Severity for every pair — free, no plan needed
  • The source, licence and sync date on every record
  • Mechanism and what to do for each pair — Growth plan
Check remimazolam against other medicinesHow interaction checks work

Remimazolam · interactions on record

71 records

  • 4 severe
  • 64 moderate
  • 3 minor

Most severe, free to view

  • MorphineN02AA01severe
  • MorphinN07BC09severe
  • HydrocodoneR05DA03severe
  • CodeineR05DA04severe
  • Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Mechanism and what to do, in the interaction check
Source: DDInter 2.0 · synced 29 Sept 2026. Grades as the source publishes them.

Same medicine, other countries

Remimazolam in 13 other countries

What each register calls a product with the same active substance — salts and hydrates count as the same.

All remimazolam products

Authorised across Europe · EMA

The same active substance is authorised in 2 EEA countries. Names it is sold under:

  • Iceland · Byfavo
  • Liechtenstein · Byfavo

Source: European Medicines Agency, Article 57 product data.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of FEST (Norway). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/5793f014-790f-463e-b1b8-5694d7956e4e
GET /v1/drugs/5793f014-790f-463e-b1b8-5694d7956e4e?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "form": "Pulver til konsentrat til injeksjons-/infusjonsvæske, oppløsning",
  "source": "fest",
  "status": "A",
  "atc_name": "Remimazolam",
  "merkevare_id": "ID_61700E03-8D4E-49B3-A12B-37F77DFEA3AD",
  "name_form_strength": "Byfavo pulver til konsentrat til injeksjons-/infusjonsvæske, oppløsning 50 mg",
  "prescription_group": "B"
}
API referenceMCP serverPlans

See everything about remimazolam.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.

Try it freeOpen in the console